These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2568824)
1. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. Kay SR; Singh MM Arch Gen Psychiatry; 1989 Aug; 46(8):711-8. PubMed ID: 2568824 [TBL] [Abstract][Full Text] [Related]
2. The positive-negative dimension in schizophrenia: its validity and significance. Kay SR; Opler LA Psychiatr Dev; 1987; 5(2):79-103. PubMed ID: 2888108 [TBL] [Abstract][Full Text] [Related]
3. Methylphenidate challenge as a predictor of relapse in schizophrenia. Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506 [TBL] [Abstract][Full Text] [Related]
4. Ceruletide for schizophrenia: a double-blind study. Mattes JA; Hom W; Rochford JM; Orlosky M Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054 [TBL] [Abstract][Full Text] [Related]
5. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Spina E; De Domenico P; Ruello C; Longobardo N; Gitto C; Ancione M; Di Rosa AE; Caputi AP Int Clin Psychopharmacol; 1994; 9(4):281-5. PubMed ID: 7868850 [TBL] [Abstract][Full Text] [Related]
6. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Danion JM; Rein W; Fleurot O Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742 [TBL] [Abstract][Full Text] [Related]
7. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048 [TBL] [Abstract][Full Text] [Related]
8. Subjective neuroleptic response and treatment outcome under open and double-blind conditions--a preliminary report. Pi E; Sramek J; Johnson T; Herrera J; Heh C; Costa J; Cutler N; Ananth J Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):921-8. PubMed ID: 1980542 [TBL] [Abstract][Full Text] [Related]
9. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196 [TBL] [Abstract][Full Text] [Related]
10. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278 [TBL] [Abstract][Full Text] [Related]
11. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. Prosser ES; Csernansky JG; Kaplan J; Thiemann S; Becker TJ; Hollister LE J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880 [TBL] [Abstract][Full Text] [Related]
12. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia. Jarema M; Kacperczyk J; Kruszynski S Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443 [TBL] [Abstract][Full Text] [Related]
13. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Kramer MS; Last B; Getson A; Reines SA Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198 [TBL] [Abstract][Full Text] [Related]
14. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Litman RE; Su TP; Potter WZ; Hong WW; Pickar D Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795 [TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia. Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205 [TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252 [TBL] [Abstract][Full Text] [Related]
17. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
18. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345 [TBL] [Abstract][Full Text] [Related]
19. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study. Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905 [TBL] [Abstract][Full Text] [Related]
20. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]